doi: 10.1074/jbc.271.34.20608
The FDA has issued safety communications regarding compounded GLP-1 receptor agonists, including tirzepatide and semaglutide, warning about adverse events from bacterial contamination, incorrect dosing, and use of improper ingredients
10.1093/jnci/djt430 365 ZuccaF
Similarly, in the combined case-control and cohort study by Wium-Andersen and colleagues, 33 low doses of metformin, DPP-4 inhibitors, GLP-1 analogs, and SGLT2 inhibitors were associated with a lower risk of depression in patients with diabetes compared to non users, with the lowest risk for sodium-glucose transport protein 2 inhibitor users
New concerns for neurocognitive function during deep space exposures to chronic, low dose rate, neutron radiation
books, ebooks, audio books and similar subscriptions